Qu Biologics Introduces Travel Subsidy Program for Crohn's Clinical Trial Participants

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 30, 2013) - Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs) that aim to "reboot" the body's immune system, announced that it has received ethics approval to implement a program to help subsidize travel and hotel costs for participants of its Crohn's disease clinical trial.

"In response to participant interest from across Canada we felt it was important to offer a travel and hotel allowance to minimize any financial burden to participants of our Crohn's clinical trial," said Dr. Hal Gunn. "The travel subsidy program will be beneficial to participants already enrolled as well as those considering enrolling," Dr. Gunn commented.

Participants of Qu Biologics' Crohn's clinical trial living more than 150 kilometres from the trial site in downtown Vancouver, B.C. will be eligible to receive an allowance to help subsidize travel and hotel costs. Travel allowances will be paid out in three equal installments, one after each of the participant's three visits to the trial site. To learn more about the Qu Crohn's trial travel subsidy program, visit: http://www.qucrohnstrial.com/trial-info/travel-allowance/.

About Qu Biologics

Qu Biologics develops Site Specific Immunomodulators (SSI), a novel class of immunotherapies that aim to reboot the body's immune system. SSIs are designed to stimulate an immune response in targeted organs or tissues to potentially reverse the chronic inflammation underlying many conditions including cancer and autoimmune disease.

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease; and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control in Canada and internationally. For more information, visit www.qubiologics.com and www.qucrohnstrial.com.